Zobrazeno 1 - 10
of 11
pro vyhledávání: '"J T, Holmlund"'
Autor:
Treen C. M. Morris, T Lissitchkov, Dominic Culligan, J W Oliver, Barry W. Hancock, David Watkins, J T Holmlund, Christopher Fegan, David Cunningham, Peter Johnson, Peter Selby, D Dunlop, Stephen Schey, Sheela Rao
Publikováno v:
Annals of Oncology. 15:1413-1418
Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma Background: The purpose of this study was to assess the efficacy and safety of ISIS 3521, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99ed3abacab1d1e5039c1a0ebb6b07eb
https://doi.org/10.1093/annonc/mdh359
https://doi.org/10.1093/annonc/mdh359
Autor:
Guru Sonpavde, J. R. Caton, V. Matveev, Matthew D. Galsky, William R. Berry, Lance Leopold, M. Brookes, M.T. Fleming, John M. Burke, Thomas E. Hutson, J. T. Holmlund, Brian A. Wood, P. A. Karlov
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 23(7)
Background AT-101 (A), a small molecule oral inhibitor of the Bcl-2 family, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC). A randomized, double-blind, pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17f35a1e492183b9f139f02987d5cec8
https://pubmed.ncbi.nlm.nih.gov/22112969
https://pubmed.ncbi.nlm.nih.gov/22112969
Publikováno v:
Current opinion in molecular therapeutics. 1(3)
Antisense oligonucleotides offer the promise of therapeutic effect with few toxic effects, by virtue of their high selectivity. Preclinical studies have provided evidence of antisense effects in vitro and in vivo, and phase I clinical trials have dem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2f97a02513c9562c487904e7b33122fa
https://pubmed.ncbi.nlm.nih.gov/11713802
https://pubmed.ncbi.nlm.nih.gov/11713802
Autor:
C C, Cunningham, J T, Holmlund, R S, Geary, T J, Kwoh, A, Dorr, J F, Johnston, B, Monia, J, Nemunaitis
Publikováno v:
Cancer. 92(5)
Abnormal expression of Ras proteins frequently is found with oncogenic transformation making ras a promising therapeutic target. ISIS 2503 is a 20-base antisense phosphorothioate oligodeoxyribonucleotide that specifically downregulates H-ras expressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4045a3bbb97dc24d2076dd3146673644
https://pubmed.ncbi.nlm.nih.gov/11571742
https://pubmed.ncbi.nlm.nih.gov/11571742
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(5)
Raf proteins play a central role in the mitogen-activated protein kinase signaling pathway and hence are involved in oncogenic transformation and tumor cell proliferation. ISIS 5132 is a 20-base antisense phosphorothioate oligodeoxyribonucleotide tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7d5fac08bbe4b2c8c0079d1c80bc97ff
https://pubmed.ncbi.nlm.nih.gov/10815875
https://pubmed.ncbi.nlm.nih.gov/10815875
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(11)
Protein kinase C (PKC) is an attractive target in cancer therapy. It is overexpressed in a variety of cancers, and nonspecific inhibitors of PKC have demonstrated antitumor activity. Antisense oligonucleotides targeted against PKC-alpha, which have h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d53cb54b62a366b9a667164ef10dcf26
https://pubmed.ncbi.nlm.nih.gov/10589745
https://pubmed.ncbi.nlm.nih.gov/10589745
Autor:
L L, Miller, E L, Korn, D S, Stevens, J E, Janik, B L, Gause, W C, Kopp, J T, Holmlund, B D, Curti, M, Sznol, J W, Smith, W J, Urba, S E, Donegan, T M, Watson, D L, Longo
Publikováno v:
Blood. 93(10)
This dose-escalation study was performed to evaluate the hematologic activity, biological effects, immunogenicity, and toxicity of PIXY321 (an interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein) administered after high-dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::32ce936eb3ac3958428383a72b17d6f2
https://pubmed.ncbi.nlm.nih.gov/10233876
https://pubmed.ncbi.nlm.nih.gov/10233876
Autor:
W C, Kopp, J T, Holmlund
Publikováno v:
Cancer chemotherapy and biological response modifiers. 16
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3615be92515844615604f0b8605618dd
https://pubmed.ncbi.nlm.nih.gov/8639383
https://pubmed.ncbi.nlm.nih.gov/8639383
Autor:
Guru Sonpavde, M. T. Fleming, Brian A. Wood, Vsevolod Matveev, P. A. Karlov, J. R. Caton, J. T. Holmlund, Lance Leopold, M. Brookes, John M. Burke
Publikováno v:
Journal of Clinical Oncology. 29:125-125
125 Background: AT-101 (A), a small molecule oral inhibitor of the Bcl-2 protein family has broad preclinical activity including synergy with docetaxel (D). AT-101 has demonstrated activity alone and in combination with D in D-refractory patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0274381fc83cba84432fc355610cb437
https://doi.org/10.1200/jco.2011.29.7_suppl.125
https://doi.org/10.1200/jco.2011.29.7_suppl.125
Autor:
J T, Holmlund
Publikováno v:
Cancer chemotherapy and biological response modifiers. 14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2f2966100d158f4de85b23b54650053f
https://pubmed.ncbi.nlm.nih.gov/7508728
https://pubmed.ncbi.nlm.nih.gov/7508728